Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Yahoo! Finance
Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary - Moby Commercial Execution and Strategic Positioning Achieved full-year profitability and positive cash flow within nine months of the VYKAT XR launch, driven by strong adoption in the PWS market. Captured approximately 12.5% of the addressable U.S. market by year-end, with 859 patients on active treatment and 1,250 total start forms received. Attributed durable growth to high prescriber engagement, with 630 unique prescribers and significant utilization across both pediatric and adult (ages 27-45) populations. Maintained a real-world safety profile consistent with clinical trials, reporting a 12% discontinuation rate due to adverse events against a total discontinuation rate of 15%. Secured broad payer coverage for over 180 million lives, with management noting that the reauthorization process has been efficient due to recognized unmet need in hyperphagia. Strategic expansion beyond PWS is focused on Glycogen Sto
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Soleno Therapeutics (SLNO) had its price target lowered by HC Wainwright from $120.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy [Yahoo! Finance]Yahoo! Finance
- Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 – Here's Why [Yahoo! Finance]Yahoo! Finance
- Soleno Profitability Milestone And CFO Shift Raise Valuation Questions [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics (SLNO) had its price target lowered by Wells Fargo & Company from $114.00 to $110.00. They now have an "overweight" rating on the stock.MarketBeat
SLNO
Earnings
- 2/25/26 - Beat
SLNO
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 3
- 2/26/26 - Form 8-K
- SLNO's page on the SEC website